Midi Health: Specific Patient Profiles That Should Look Elsewhere (and Why)

Is Midi Health Legit?

Midi Health is a legitimate, accredited telehealth company focused exclusively on women in perimenopause and menopause. The platform holds LegitScript accreditation, maintains an A+ Better Business Bureau rating, and employs clinicians who are licensed in each state where they practice. Prescriptions are transmitted to licensed U.S. Pharmacies only.

What Accreditation Actually Means

LegitScript accreditation is the pharmacy-industry standard for online healthcare companies. It requires verification of prescriber licensing, compliance with state telehealth laws, and adherence to DEA controlled-substance regulations. Midi Health meets all three tiers. That is a meaningful credential, not a marketing badge.

The Clinician Roster

Midi Health staffs nurse practitioners, certified nurse-midwives, and physicians, all with documented menopause-specific training. The Menopause Society (formerly NAMS) recommends that clinicians managing menopausal hormone therapy complete formal menopause education, and Midi Health states its providers complete that training before seeing patients. The Menopause Society's 2023 position statement notes that "most women who are considering MHT are appropriate candidates" but that individualized risk stratification by a trained clinician remains the standard of care.

Complaints and Real Limitations

The BBB file shows fewer than 10 formal complaints as of January 2025, mostly related to billing disputes and appointment wait times rather than clinical errors. Those categories are common across all telehealth platforms. A more substantive limitation: Midi Health cannot order or review imaging, cannot perform physical exams, and does not replace gynecologic cancer screening. Patients who conflate a Midi Health subscription with comprehensive gynecologic care may miss time-sensitive diagnoses.

Who Should NOT Use Midi Health

This is the central clinical question. Several patient profiles carry enough risk or complexity that Midi Health's asynchronous-plus-video model is insufficient.

Profile 1: Active or Recent Hormone-Sensitive Cancer

Women with an active estrogen-receptor-positive (ER+) breast cancer diagnosis, or those within five years of completing treatment for ER+ breast cancer, should not start systemic estrogen through any telehealth platform without direct coordination with their oncologist. Midi Health's intake form screens for cancer history, but the platform is not designed to co-manage oncology patients in real time.

The FDA's prescribing information for estradiol products lists known or suspected estrogen-dependent neoplasias as a contraindication to systemic estrogen therapy. Midi Health clinicians follow that guidance, which in practice means ER+ breast cancer patients will be declined or referred out. Knowing this before you book a visit saves time and avoids a frustrating consultation.

Uterine (endometrial) cancer history is a similar contraindication for unopposed estrogen. Women with an intact uterus who have prior endometrial cancer need oncology-supervised hormonal decisions, not a telehealth visit.

Profile 2: Recent Venous Thromboembolism or Clotting Disorders

Oral estrogen raises VTE risk. The Women's Health Initiative (WHI) trial (N=16,608) found that oral conjugated equine estrogen plus medroxyprogesterone acetate was associated with a hazard ratio of 2.06 for VTE compared to placebo [1]. Transdermal estrogen carries a substantially lower thrombotic risk, and a 2015 BMJ meta-analysis (N=80,396 women across 36 studies) showed that transdermal estradiol did not significantly increase VTE risk compared to non-use [2].

Even so, women with a documented Factor V Leiden mutation, antiphospholipid syndrome, or a VTE event within the prior 12 months require hematology or coagulation specialist input before any hormonal prescription. Midi Health clinicians can prescribe transdermal options and will screen for clotting history, but patients with active anticoagulation or newly diagnosed thrombophilias belong in a coordinated specialty setting where monthly labs and dose adjustments can be tracked in a shared record system.

Profile 3: Uncontrolled Hypertension or Recent Cardiac Events

The American Heart Association's 2020 menopause guidelines state that menopausal hormone therapy should not be used for primary or secondary cardiovascular disease prevention and that women with uncontrolled hypertension (systolic above 160 mmHg or diastolic above 100 mmHg) require blood pressure optimization before hormonal initiation [3]. A telehealth provider cannot measure your blood pressure in the office.

Midi Health can review self-reported BP readings and ask patients to submit recent lab results, but it cannot perform an auscultated exam, order an echocardiogram, or coordinate directly with a cardiologist's EHR. Women who had a myocardial infarction or stroke within the prior 12 months, or who have decompensated heart failure, need in-person cardiovascular oversight. A Midi Health clinician will likely decline to prescribe systemic HRT to these patients and refer them to cardiology, which is the correct clinical call, but it means the visit does not accomplish what the patient needed.

Profile 4: Complex Thyroid or Adrenal Disease as the Primary Concern

Midi Health focuses on menopausal hormone therapy and non-hormonal menopause symptom management. If your primary complaint is persistent fatigue, weight gain, or mood disruption, Midi Health will screen for thyroid dysfunction via lab order. They will not serve as your ongoing thyroid manager. Women with Hashimoto's thyroiditis requiring frequent levothyroxine titration, or with adrenal insufficiency on hydrocortisone replacement, need a single provider or a coordinated endocrine team that can see them in person.

Menopausal symptom overlap with hypothyroidism is clinically well-documented. A 2021 review in the Journal of Clinical Endocrinology and Metabolism found that vasomotor symptoms, cognitive fog, and sleep disruption appear in both conditions, making accurate diagnosis dependent on serial lab trending and clinical context [4]. Midi Health can order an initial TSH and free T4, but ongoing endocrine titration is outside its core model.

Profile 5: Patients Who Need Testosterone Therapy Above Female Physiologic Range

Midi Health does prescribe testosterone for women, most commonly as a low-dose topical preparation for hypoactive sexual desire disorder (HSDD) or energy complaints. The platform does not prescribe testosterone at male-range doses and is not designed for gender-affirming hormone therapy or bodybuilding-adjacent use cases. Women who need higher-dose testosterone or who are undergoing gender transition should seek a provider specializing in gender-affirming care.

The framework below summarizes the five profiles and the suggested alternative care pathway for each.

| Profile | Clinical Reason Midi Health Is Insufficient | Suggested Alternative | |---|---|---| | ER+ breast cancer (active or recent) | Systemic estrogen is contraindicated; oncology coordination required | Oncology-supervised MHT or non-hormonal options with oncologist | | Active VTE or severe thrombophilia | Complex anticoagulation management exceeds telehealth scope | Hematology plus OB-GYN or endocrinology in-person | | Uncontrolled hypertension or recent cardiac event | BP optimization and cardiac monitoring require in-person oversight | Cardiologist co-management before any HRT initiation | | Complex thyroid or adrenal disease as primary complaint | Serial endocrine titration needs coordinated in-person follow-up | Endocrinologist or internal medicine with telehealth supplement | | Testosterone above female physiologic range needed | Outside Midi Health prescribing scope | Gender-affirming care specialist or men's health TRT provider |

What Midi Health Does Well (Context for the Criticism)

Criticizing a platform without context is not useful. Midi Health fills a real gap. The Menopause Society 2023 position statement noted that fewer than 25% of U.S. OB-GYNs feel adequately trained to manage menopausal hormone therapy, creating a structural access problem for tens of millions of perimenopausal women [5].

Insurance Acceptance

Most menopause telehealth competitors operate cash-pay only. Midi Health accepts Aetna, Cigna, UnitedHealthcare, Blue Cross Blue Shield plans, and Medicare in select states. For a patient paying a $20, $40 specialist copay versus $150, $250 per visit at a cash-pay competitor, that difference is financially meaningful.

Breadth of Non-Hormonal Options

Not every perimenopausal woman is a candidate for systemic estrogen, and Midi Health prescribes evidence-based non-hormonal alternatives. Paroxetine 7.5 mg (Brisdelle) is the only FDA-approved non-hormonal vasomotor symptom treatment, and Midi Health clinicians can prescribe it. They also prescribe fezolinetant (Veozah), which the FDA approved in May 2023 for moderate-to-severe vasomotor symptoms based on the SKYLIGHT 1 and SKYLIGHT 2 trials, where 12 weeks of fezolinetant 45 mg daily reduced the frequency of moderate-to-severe hot flashes by 59 to 65% versus 34 to 37% for placebo [6].

Speed of Access

The average wait time for a new gynecology appointment in the United States exceeded 26 days as of a 2023 Merritt Hawkins access survey. Midi Health typically schedules initial visits within 3 to 7 days. For a woman in acute vasomotor distress affecting sleep and work function, that timeline difference is not trivial.

Midi Health Complaints: What the Data Actually Shows

Reviewing the BBB complaint history and community forums (including the r/Menopause subreddit and Trustpilot as of January 2025) reveals a consistent pattern of complaint types.

Billing and Insurance Denials

The most common complaint is not clinical. It relates to surprise bills when insurance authorization is denied retroactively, or when patients are seen by a clinician not in their specific network tier. This is a systemic U.S. Telehealth billing problem, not a Midi Health-specific failure, but patients should verify in-network status before their first appointment and ask explicitly whether their assigned clinician is in-network under their specific plan.

Appointment Wait Times at Peak Hours

Some patients report difficulty rescheduling or longer-than-expected video wait times. This appears to be a staffing-to-demand mismatch during peak enrollment periods, not a structural clinical problem. Patients with urgent complaints (breakthrough bleeding on HRT, for example) should be directed to their primary care provider or urgent care while waiting, because telehealth throughput cannot serve as emergency triage.

Perceived Over-Reliance on Standardized Protocols

A minority of forum complaints describe clinicians who followed protocol-driven approaches rather than individualizing care. This is both a strength (consistency, safety) and a limitation (less flexibility for unusual presentations). Women with atypical symptom clusters, multiple comorbidities, or prior failed HRT trials may find a menopause-specialist OB-GYN in their city more responsive to nuanced clinical history.

State Availability and Regulatory Compliance

Midi Health operates under state telehealth laws, which vary significantly. As of January 2025, it operates in 45+ states. It does not currently serve patients in states where it lacks a licensed prescriber. Patients in rural states or those who have recently moved should confirm current state availability before booking.

The FDA's guidance on telehealth prescribing requires that a valid patient-provider relationship exist before any prescription is issued. Midi Health establishes this through a synchronous video visit, which meets the standard in all states where it operates [7].

How to Decide: A Practical Pre-Enrollment Checklist

Before booking a Midi Health appointment, run through these five questions.

1. Do you have a personal or family history of ER+ breast cancer? If yes, speak with your oncologist before booking.
2. Have you had a blood clot, pulmonary embolism, or been diagnosed with a clotting disorder? If yes, a hematology consultation should come first.
3. Is your systolic blood pressure consistently above 160 mmHg without controlled medication? Stabilize BP with your primary care provider first.
4. Are you seeking testosterone doses above the female physiologic range, or gender-affirming hormone therapy? Midi Health is the wrong platform.
5. Is your primary complaint thyroid- or adrenal-related rather than menopause-specific? Start with endocrinology, not a menopause telehealth service.

If you answered no to all five, Midi Health is worth a serious look, particularly if your insurer is in-network. Women who answered yes to any of them are not being rejected for trivial reasons. The contraindications above reflect the same clinical logic that a board-certified OB-GYN would apply in an office visit.

The ACOG Practice Bulletin No. 141 on menopausal hormone therapy states that clinicians should individualize therapy based on personal risk factors, symptom severity, and patient preferences, with a formal shared decision-making process [8]. That shared decision-making process requires honest disclosure of your full medical history, whether you are in a telehealth visit or an office exam room.

Women with moderate-to-severe vasomotor symptoms and no contraindications should know that the Menopause Society's 2023 data found menopausal hormone therapy to be the most effective treatment for hot flashes, with some formulations reducing frequency by more than 75% in randomized trials [5]. Getting access to that treatment efficiently and safely, through a platform like Midi Health or through an in-person specialist, is a decision worth making carefully.

The single most important step before enrolling in any telehealth HRT service: bring your most recent labs (TSH, CBC, lipid panel, and a pelvic exam or Pap within the last three years) to your first visit. Midi Health clinicians can do more with that context than with a blank intake form.